These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 21149474)

  • 21. [Predictive value of the early metabolic response in patients with advanced-stage non-small cell lung cancer].
    Moreno C; Mourelo S; Soler M; Moragas M; Riera E; Garcia JR
    Rev Esp Med Nucl Imagen Mol; 2014; 33(5):324-5. PubMed ID: 24418117
    [No Abstract]   [Full Text] [Related]  

  • 22. Current standards and new concepts in MRI and PET response assessment of antiangiogenic therapies in high-grade glioma patients.
    Hutterer M; Hattingen E; Palm C; Proescholdt MA; Hau P
    Neuro Oncol; 2015 Jun; 17(6):784-800. PubMed ID: 25543124
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Lung infarction--a diagnostic challenge in the oncologic patient?].
    Hinrichs J; Bengel F; Wacker F; Vogel-Claussen J
    Rofo; 2013 Oct; 185(10):915-9. PubMed ID: 24490239
    [No Abstract]   [Full Text] [Related]  

  • 24. Dynamic T1-weighted magnetic resonance imaging and positron emission tomography in patients with lung cancer: correlating vascular physiology with glucose metabolism.
    Hunter GJ; Hamberg LM; Choi N; Jain RK; McCloud T; Fischman AJ
    Clin Cancer Res; 1998 Apr; 4(4):949-55. PubMed ID: 9563889
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prediction of response to targeted therapies in lung cancer using dynamic imaging: still far from clinical implementation.
    Quintela-Fandino M; Colomer R
    J Clin Oncol; 2011 Sep; 29(27):3716-8; author reply 3718-9. PubMed ID: 21860002
    [No Abstract]   [Full Text] [Related]  

  • 26. Serial PET scans demonstrate the success and limitations of antiangiogenic treatment in a case of lung adenocarcinoma.
    Zhu Z; Li F
    Clin Nucl Med; 2008 Sep; 33(9):635-7. PubMed ID: 18716517
    [No Abstract]   [Full Text] [Related]  

  • 27. Dynamic contrast-enhanced MRI parameters as biomarkers for the effect of vatalanib in patients with non-small-cell lung cancer.
    Nensa F; Stattaus J; Morgan B; Horsfield MA; Soria JC; Besse B; Gounant V; Khalil A; Seng K; Fischer B; Krissel H; Laurent D; Christoph D; Eberhardt WE; Gauler TC
    Future Oncol; 2014 Apr; 10(5):823-33. PubMed ID: 24799063
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Application of Bevacizumab in Non-small Cell Lung Cancer].
    Xu P; Li H
    Zhongguo Fei Ai Za Zhi; 2017 Apr; 20(4):272-277. PubMed ID: 28442017
    [TBL] [Abstract][Full Text] [Related]  

  • 29. State of the Art Treatment and Surveillance Imaging of Glioblastomas.
    Margiewicz S; Cordova C; Chi AS; Jain R
    Semin Roentgenol; 2018 Jan; 53(1):23-36. PubMed ID: 29405952
    [No Abstract]   [Full Text] [Related]  

  • 30. Magnetic resonance imaging-based oxygen challenge technique replaced PET in ischemic penumbra.
    Kim JG; Kim JE
    Neurosurgery; 2012 Aug; 71(2):N15-8. PubMed ID: 22811199
    [No Abstract]   [Full Text] [Related]  

  • 31. Evaluating the impact of magnetic resonance imaging on patients with operable non-small-cell lung cancer and unilateral adrenal masses: importance of appropriate technique.
    Mitchell DG
    J Thorac Cardiovasc Surg; 1995 Apr; 109(4):814-5. PubMed ID: 7715236
    [No Abstract]   [Full Text] [Related]  

  • 32. Commentary on "Positron Emission Tomography in the Lung" 25 years after publication in the inaugural issue of the Journal of Thoracic Imaging.
    Patz EF; Erasmus JJ
    J Thorac Imaging; 2010 Feb; 25(1):39-40. PubMed ID: 20160601
    [No Abstract]   [Full Text] [Related]  

  • 33. National versus international generalizations from cost-effectiveness analyses.
    Lyles A
    Clin Ther; 2011 Oct; 33(10):1444-5. PubMed ID: 22036130
    [No Abstract]   [Full Text] [Related]  

  • 34. Predicting tumour response.
    Kyle SD; Law WP; Miles KA
    Cancer Imaging; 2013 Sep; 13(3):381-90. PubMed ID: 24061161
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Whole-body parametric mapping of tumour perfusion in metastatic prostate cancer using long axial field-of-view [
    Jochumsen MR; Christensen NL; Iversen P; Gormsen LC; Sørensen J; Tolbod LP
    Eur J Nucl Med Mol Imaging; 2024 Nov; 51(13):4134-4140. PubMed ID: 38940842
    [TBL] [Abstract][Full Text] [Related]  

  • 36. PET Imaging of Metabolism, Perfusion, and Hypoxia: FDG and Beyond.
    Pantel AR; Bae SW; Li EJ; O'Brien SR; Manning HC
    Cancer J; 2024 May-Jun 01; 30(3):159-169. PubMed ID: 38753750
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Molecular and functional imaging in cancer-targeted therapy: current applications and future directions.
    Bai JW; Qiu SQ; Zhang GJ
    Signal Transduct Target Ther; 2023 Feb; 8(1):89. PubMed ID: 36849435
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Characterization of spatially mapped volumetric molecular ultrasound signals for predicting response to anti-vascular therapy.
    Keller CA; Zarkesh S; Zhou J; Lutz AM; Hristov D; Kamaya A; El Kaffas A
    Sci Rep; 2023 Jan; 13(1):1686. PubMed ID: 36717575
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dynamic contrast enhanced MRI of pulmonary adenocarcinomas for early risk stratification: higher contrast uptake associated with response and better prognosis.
    Rheinheimer S; Christopoulos P; Erdmann S; Saupe J; Golpon H; Vogel-Claussen J; Dinkel J; Thomas M; Heussel CP; Kauczor HU; Heussel G
    BMC Med Imaging; 2022 Dec; 22(1):215. PubMed ID: 36471318
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Radiomics-Based Deep Learning Prediction of Overall Survival in Non-Small-Cell Lung Cancer Using Contrast-Enhanced Computed Tomography.
    Hou KY; Chen JR; Wang YC; Chiu MH; Lin SP; Mo YH; Peng SC; Lu CF
    Cancers (Basel); 2022 Aug; 14(15):. PubMed ID: 35954461
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.